Clinical trial
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
NCT00230334 · Steven E. Coutre, Other · Terminated
Key facts
| NCT number | NCT00230334 |
|---|---|
| Title | Phase II Gleevec Idiopathic Hypereosinophilic Syndrome |
| Official title | Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES) |
| Lead sponsor | Steven E. Coutre, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Eosinophilia, Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | Gleevec |
| Enrollment | 5 |
| Start date | Jun 12, 2003 |
| Primary completion | Dec 29, 2006 |
| Completion | May 1, 2007 |
| First posted | Sep 30, 2005 |
| Last update posted | May 10, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: